BrianGWeinshenkerMD
Neurology • Charlottesville, VANeuroimmunology/Multiple Sclerosis
Professor, Neurology, University of Virginia
Dr. Weinshenker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Box 800394 McKim Hall
University of Virginia
Charlottesville, VA 22903Phone+1 434-982-6410- Is this information wrong?
Summary
- Dr. Brian Weinshenker is a neurologist who practiced for 30 years at Mayo Clinic, Rochester MN and recently moved to the University of Virginia. He received his medical degree from University of Manitoba and has been in practice 42 years. He is experienced in general neurology, clinical research, spinal cord disorders, and neuroimmunology (multiple sclerosis).
Education & Training
University of MinnesotaResidency, Neurology, 1982 - 1985
University of ManitobaClass of 1978
Certifications & Licensure
VA State Medical License 2022 - 2026
MN State Medical License 1992 - 2022
FL State Medical License 2017 - 2021- American Board of Internal Medicine Internal Medicine
- Royal College of Physicians and Surgeons of CanadaPsychiatry and Neurology
Clinical Trials
- Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Start of enrollment: 2016 Feb 01
Publications & Presentations
PubMed
- MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Commentary.Weinshenker, B.> ;Multiple Sclerosis. 2024 Jan 1
- Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clini...Sara Samadzadeh, Mads Nikolaj Olesen, Martin Wirenfeldt, Sören Möller, Tatsuro Misu, Kerstin Soelberg, Jette Lautrup Frederiksen, Steffen Heegaard, Sara Mariotto, Kazu...> ;Multiple Sclerosis. 2023 Dec 1
- Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.Ho Jin Kim, Orhan Aktas, Kristina R Patterson, Schaun Korff, Amy Kunchok, Jeffrey L Bennett, Brian G Weinshenker, Friedemann Paul, Hans-Peter Hartung, Daniel Cimbora, ...> ;Annals of Clinical and Translational Neurology. 2023 Dec 1
- Join now to see all
Journal Articles
- Diagnosis of Progressive Multiple Sclerosis from the Imaging PerspectiveBrian G Weinshenker, Brenda L Banwell, JAMA Neurology
- Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients with Myelin Oligodendrocyte Glycoprotein IgG–Associated DisordersAmy Kunchok, Brian G Weinshenker, Eoin P Flanagan, Sean J Pittock, JAMA Neurology
- Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System EventsAmy Kunchok, Allen J Aksamit, Sean J Pittock, Brian G Weinshenker, Andrew Mckeon, JAMA Neurology
- Join now to see all
Authored Content
- Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients with Myelin Oligodendrocyte Glycoprotein IgG–Associated DisordersAugust 2020
- Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System EventsMay 2020
Press Mentions
CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-Mediated DiseasesJuly 6th, 2022- Mayo Clinic Research in the News — 7/26/2021July 26th, 2021
- Suffering with Hiccups That Never Seem to Go AwayJuly 24th, 2021
- Join now to see all
Grant Support
- Interferon Gamma Polymorphisms And Gender Bias In MSNational Institute Of Neurological Disorders And Stroke2004
- Interferon Gamma Polymorphisms And Gender Bias In MSNational Institute Of Neurological Disorders And Stroke2002–2003
- Plasma Exchange In Severe Demyelinating DiseaseNational Institute Of Neurological Disorders And Stroke1995–1999
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
